ReviewCurrent allergy and asthma reports2015
Eosinophilic Esophagitis and Gastroenteritis.
Review in Current allergy and asthma reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 85 citations in OpenAlex.
- Eosinophilic gastrointestinal diseases.Nature reviews. Disease primers · 2026Review
- Article
- Unraveling the enigma of eosinophilic gastroenteritis: a rare case of multisystem involvement in an elderly patient.Oxford medical case reports · 2026Article
- Age-Dependent Clinical Manifestations of Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis.Journal of asthma and allergy · 2025Article
- A Patient With Eosinophilic Gastroenteritis Presenting With Severe Abdominal Pain.Clinical case reports · 2024Article
- Clinical and atopic features of patients with primary eosinophilic colitis: an Italian multicentre study.Internal and emergency medicine · 2024Article
- Article
- An efficient computational framework for gastrointestinal disorder prediction using attention-based transfer learning.PeerJ. Computer science · 2024Article
- Identification of CXC Chemokine Receptor 2 (CXCR2) as a Novel Eosinophils-Independent Diagnostic Biomarker of Pediatric Eosinophilic Esophagitis by Integrated Bioinformatic and Machine-Learning Analysis.ImmunoTargets and therapy · 2024Article
- Article
- Local type 2 immunity in eosinophilic gastritis.The Journal of allergy and clinical immunology · 2023Article
- Update on eosinophilic gastrointestinal disease beyond eosinophilic esophagitis in children.Clinical and experimental pediatrics · 2023Article
- Mortality and cancer in eosinophilic gastrointestinal disorders distal to the esophagus: nationwide cohort study 1990-2017.Journal of gastroenterology · 2022Article
- Primary eosinophilic gastrointestinal disorders and allergy: Clinical and therapeutic implications.Clinical and translational allergy · 2022Review
- Development and content validation of a symptom assessment for eosinophilic gastritis and eosinophilic gastroenteritis in adults and adolescents.Orphanet journal of rare diseases · 2021Article
- Episodic Angioedema with Hypereosinophilia (Gleich's Syndrome): A Case Report and Extensive Review of the Literature.Journal of clinical medicine · 2021Review
- Potential Mechanisms of Acupuncture for Functional Dyspepsia Based on Pathophysiology.Frontiers in neuroscience · 2021Review
- Malnutrition in Eosinophilic Gastrointestinal Disorders.Nutrients · 2020Review
- Eosinophilic gastroenteritis with gastric perforation-An unusual presentation.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020Article
- A case report of eosinophilic gastroenteritis misdiagnosed as cholelithiasis.Clinical case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic gastrointestinal disease (EGID) can be classified as eosinophilic esophagitis (EoE) when the eosinophilia is limited to the esophagus or as eosinophilic gastritis (EG) if it is limited to the gastric tract, eosinophilic colitis (EC) if it is limited to the colon, and eosinophilic gastroenteritis (EGE) if the eosinophilia involves one or more parts of the gastrointestinal tract. EoE is by far the most common EGID. It is a well-defined chronic atopic disease due to a T helper type 2 (Th2) inflammation triggered often by food allergens. EoE diagnosis is done if an esophageal biopsy shows at least 15 eosinophils per high power field (eos/hpf). Globally accepted long-term therapies for EoE are the use of swallowed inhaled steroids or food antigen avoidance. The treatment of EoE is done not only to control symptoms but also to prevent complications such as esophageal stricture and food impaction. EGE cause non-specific gastrointestinal (GI) symptoms and are diagnosed if esophagogastroduodenoscopy (EGD)/colonoscopy show eosinophilia in one or more parts of the GI tract. They are rare diseases with an unclear pathogenesis, and they are poorly defined in terms of diagnostic criteria and treatment. Before initiating treatment of any EGE, it is imperative to conduct a differential diagnosis to exclude other causes of hypereosinophilia with GI localization. EGE are often poorly responsive to therapy and there is no commonly accepted long-term treatment. EG has many characteristics similar to EoE, including the fact that it is often due to a food allergen-driven Th2 inflammation; transcriptome analysis however shows that it is more a systemic disease and has a different gene signature than EoE. EC is a benign form of delayed food allergy in infant and is instead a difficult-to-treat severe inflammatory condition in older children and adults. EC in the latter groups can be a manifestation of drug allergy or autoimmune disease. Overall EGE, EC, and EG are rare and are a diagnosis of exclusion until more common causes of eosinophilia have been excluded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.